Reference standards in relative potency assays

Relative potency assays quantify the biological activity of a test sample against a reference preparation of the same product. They are central to biopharmaceutical development because biological activity is a critical quality attribute that physicochemical methods cannot capture. Higher-order structure, post-translational modifications and the mechanism of action all contribute to it.

The reference standard is the basis of every relative potency result. Its suitability, assigned potency, stability and handling directly affect how results are interpreted. Reference standard strategy should therefore be defined early in potency assay development, alongside assay design, controls and statistical analysis.

Understanding relative potency assays.

In a relative potency assay, the test sample and the reference standard are tested side by side under identical conditions, typically on the same plate or in the same run. Each is usually tested as a dilution series to generate full dose-response curves.

The curves are fitted with an appropriate statistical model, such as a parallel-line model for the linear part of the response or a four-parameter logistic (4PL) model for sigmoidal curves. The key assumption is similarity: the test sample should behave as a dilution or concentration of the reference. If that holds, the two curves differ only by a horizontal shift on the log-dose axis, and relative potency is the ratio of equipotent doses:

For example, a test sample that reaches the same response at half the concentration of the reference has a relative potency of 200%. Relative potency is therefore a comparative measure. It should not be confused with the absolute amount of active substance, which is measured separately, for example by protein content.

ICH Q6B recommends appropriate biological assays to assess biological activity and recognizes the use of reference standards to relatively express that activity.

Why reference standards are critical.

Bioassays are inherently variable. Cell passage number, reagent lots, analysts, instruments, incubation times and plate position effects all influence the absolute response. Because the reference and test sample are exposed to the same conditions within a run, much of this run-to-run variability affects both curves equally and cancels out in the potency ratio.

The reference itself, however, cannot be corrected for in this way. If it is unstable, poorly characterized, inconsistently prepared or not representative of the product, the error carries straight into every result. A loss of activity in the reference is a systematic error: if the reference loses 10% of its activity, test samples will appear roughly 10% more potent. Within-run system suitability criteria will not detect this, because the curves can still look normal.

This is why reference standard strategy is an integral part of potency assay development. A suitable standard is a prerequisite for meaningful results, but it cannot compensate for weaknesses in assay design, controls, execution or statistical analysis.

Reference standards, reference materials and controls.

These terms are often used interchangeably, but they have distinct roles.

A reference standard is a characterized material with an assigned value for a specific analytical purpose. In a relative potency assay, it is the comparator for potency estimation. Many programs use a two-tier system: a primary reference standard, calibrated against an international standard where one exists, and a working reference standard calibrated against the primary and used in routine testing. This conserves the primary material.

A reference material is a broader term for any material used for comparison, calibration, development or other analytical purposes. Where no official standard is available, a suitably characterized in-house reference material may be established.

An assay control monitors assay performance over time, for example a sample with a known relative potency that is tested in every run and trended on a control chart. System suitability criteria, such as limits on slope, asymptotes, curve fit and parallelism, show that a run meets predefined requirements. Neither should be used as a substitute for the reference standard.

Qualification and management.

The extent of reference standard qualification should reflect its intended use and the development phase. Depending on the product and assay, it may include identity, purity and product-related variants (for example by size-exclusion chromatography or charge-variant analysis), protein content, stability and biological activity.

The assigned potency is best derived from several independent assay runs rather than a single result. Because potency estimates are approximately log-normally distributed, they are typically combined as a geometric mean with a confidence interval calculated on the log scale.

ICH Q6B states that biological activity may be expressed in units calibrated against an international or national reference standard where one exists. Where none is available, an appropriately characterized in-house reference material may be used.

Storage and handling need the same level of control. Temperature excursions, repeated freeze-thaw cycles, degradation, aggregation or inconsistent reconstitution can all change biological activity. Single-use aliquots, defined storage conditions and a stability monitoring program reduce these risks.

Anabiotec describes reference stock management, quantity monitoring and periodic requalification within its analytical method lifecycle services.

Replacing a reference standard.

Reference standards eventually need replacement because of limited supply, stability concerns, expiry or other lifecycle considerations. A new lot will not necessarily behave identically to the previous one, even when it is manufactured by the same process.

A bridging study establishes the relationship between the current and the candidate standard. The candidate is typically tested against the current standard in several independent runs, and its potency is assigned so that reported results remain continuous across the change. Similarity between the two dose-response curves should be confirmed as part of the same study.

Each replacement carries some uncertainty, and when every new standard is calibrated only against its predecessor, these small errors can accumulate over successive generations. This potency drift can be limited by calibrating new working standards against a well-maintained primary standard, or against an international standard where one exists. EMA guidance discusses reference standard qualification and the need to consider potential potency drift when establishing replacement standards.

The appropriate approach depends on the product, assay, reference material and regulatory context.

Statistics and assay interpretation.

Relative potency is estimated from comparative dose-response data, not from a single measurement. A sound analysis covers model selection, weighting or transformation of the response where variance is not constant, assessment of similarity (parallelism) and confidence intervals for the potency estimate. USP chapters <1032>, <1033> and <1034> address the design, validation and statistical analysis of biological assays. USP <1032> favors an equivalence approach for demonstrating similarity over traditional significance tests, which can reject precise assays for differences that have no practical relevance.

Results from several independent runs are usually combined on the log scale to give a reportable value with a confidence interval.

Statistical analysis is essential for interpreting relative potency, but it cannot correct for an inappropriate reference standard. This is why reference management belongs within potency assay development rather than being treated as a separate administrative task.

Reference standards throughout the method lifecycle.

Reference standard planning should continue from development through routine testing. During potency assay development, teams should consider qualification, storage, availability, potency assignment and future replacement, ideally as part of the analytical control strategy described in ICH Q14.

During validation, the reference becomes part of the controlled analytical procedure. ICH Q2(R2) emphasizes the use of suitably characterized reference materials appropriate to their intended purpose. For bioassays, validation typically addresses relative accuracy, intermediate precision, specificity and range, all of which depend on a stable and well-characterized reference.

In routine use, trending of assay control results and reference standard stability data helps detect drift before it affects batch release decisions.

Anabiotec’s published services cover assay and method development, qualification, validation, transfer and method lifecycle management, including reference standard management.

A well-defined reference strategy helps maintain consistent potency results as a method moves through its lifecycle.

Conclusion.

A relative potency result is only as reliable as the comparison between the test sample and the reference standard. Proper qualification, potency assignment, storage, handling and replacement of the reference should therefore be addressed during potency assay development, not after validation.

For pharmaceutical and biopharmaceutical teams, integrating reference standard management with assay design, controls, statistics and lifecycle planning makes potency results easier to interpret, defend and maintain over time.

Frequently asked questions.

What is a relative potency assay?

A relative potency assay compares the biological activity of a test sample with that of a reference standard under identical conditions. Provided the dose-response curves are similar, it expresses the activity of the test sample as a ratio or percentage of the reference.

Why is a reference standard used in potency testing?

A reference standard provides the comparator needed to estimate relative biological activity. Testing it alongside the sample in the same run means that much of the run-to-run variability affects both equally, giving a consistent basis for comparison.

How is a reference standard qualified?

Qualification depends on the intended use and may include identity, purity, protein content, stability and biological activity, with potency assigned from several independent assay runs. Replacement standards require a bridging study to establish their relationship with the current standard and to limit potency drift.